Arti M. Raghubar

Sep 11, 2023 | nature.com | Nicholas Matigian |Joanna Crawford |Helen Healy |Arti M. Raghubar

AbstractPerioperative immune checkpoint inhibitor (ICI) trials for intermediate high-risk clear cell renal cell carcinoma (ccRCC) have failed to consistently demonstrate improved patient outcomes. These unsuccessful ICI trials suggest that the tumour infiltrating immunophenotypes, termed here as the immune cell types, states and their spatial location within the tumour microenvironment (TME), were unfavourable for ICI treatment.